MYGN241220C23000
- 0.56
- 0.000.00%
Myriad Genetics Newsroom
Myriad Genetics' RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics
Is Myriad Genetics Stock a Smart Hold for Your Portfolio Right Now?
Myriad Genetics Is Maintained at Underperform by B of A Securities
Myriad Genetics Analyst Ratings
BofA Securities Maintains Myriad Genetics(MYGN.US) With Sell Rating, Cuts Target Price to $13
Top Premarket Decliners
Express News | Myriad Genetics Inc : Jefferies Cuts Target Price to $13 From $15
Myriad Genetics Engages With UnitedHealthcare on Access to GeneSight Test Following Policy Update
Express News | Negotiations between Myriad and UnitedHealth Insurance may extend to early 2025.
Myriad Genetics Talks With UnitedHealthcare on Insurance Exclusion Might Extend Into 2025
Myriad Genetics: During 3Q Earnings Call Provided Estimate of 2024 Fincl Impact of UNH's Updated Medical Policy, Myriad Reaffirms Estimate >MYGN
Myriad Genetics: Engaged in Dialogue With UNH Regarding Clinical Evidence Supporting Myriad's Proprietary and Clinically Differentiated Mental Health Medication Test GeneSight >MYGN
Myriad Genetics: Desire Resolution Ahead of Yr-End, But Discussions May Extend Into Early 2025 >MYGN
Express News | Myriad Genetics Provides Update on Discussions With Unitedhealthcare Regarding Medical Policy for Pharmacogenetic Testing
Myriad Genetics Provides Update on Discussions With UnitedHealthcare Regarding Medical Policy for Pharmacogenetic Testing
Express News | Myriad Genetics : Approved an Increase in Size of Board From Eight to Nine Members
Press Release: Myriad Genetics Expands Board of Directors With Election of Mark S. Davis as New Board Member
Express News | Myriad Genetics Expands Board of Directors With Election of Mark S. Davis as New Board Member
Myriad Genetics Initiated at Neutral by UBS
Express News | Myriad Genetics’ Portfolio Elevated by Updated Nccn Prostate Cancer Guidelines